198 related articles for article (PubMed ID: 21208906)
1. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Bachleitner-Hofmann T; Sun MY; Chen CT; Liska D; Zeng Z; Viale A; Olshen AB; Mittlboeck M; Christensen JG; Rosen N; Solit DB; Weiser MR
Clin Cancer Res; 2011 Jan; 17(1):122-33. PubMed ID: 21208906
[TBL] [Abstract][Full Text] [Related]
2. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
3. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
[TBL] [Abstract][Full Text] [Related]
4. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
5. The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.
Liu KS; Ding WC; Wang SX; Liu Z; Xing GW; Wang Y; Wang YF
Oncol Rep; 2012 Jun; 27(6):1904-10. PubMed ID: 22447251
[TBL] [Abstract][Full Text] [Related]
6. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Rice JW; Veal JM; Barabasz A; Foley B; Fadden P; Scott A; Huang K; Steed P; Hall S
Oncol Res; 2009; 18(5-6):229-42. PubMed ID: 20225761
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
Ou WB; Hubert C; Corson JM; Bueno R; Flynn DL; Sugarbaker DJ; Fletcher JA
Neoplasia; 2011 Jan; 13(1):12-22. PubMed ID: 21245936
[TBL] [Abstract][Full Text] [Related]
8. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.
Okawa Y; Hideshima T; Steed P; Vallet S; Hall S; Huang K; Rice J; Barabasz A; Foley B; Ikeda H; Raje N; Kiziltepe T; Yasui H; Enatsu S; Anderson KC
Blood; 2009 Jan; 113(4):846-55. PubMed ID: 18948577
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
10. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
[TBL] [Abstract][Full Text] [Related]
11. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
[TBL] [Abstract][Full Text] [Related]
12. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.
Musiani D; Konda JD; Pavan S; Torchiaro E; Sassi F; Noghero A; Erriquez J; Perera T; Olivero M; Di Renzo MF
FASEB J; 2014 Sep; 28(9):4055-67. PubMed ID: 24903273
[TBL] [Abstract][Full Text] [Related]
13. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
14. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
Qi J; McTigue MA; Rogers A; Lifshits E; Christensen JG; Jänne PA; Engelman JA
Cancer Res; 2011 Feb; 71(3):1081-91. PubMed ID: 21266357
[TBL] [Abstract][Full Text] [Related]
15. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.
Petti C; Picco G; Martelli ML; Trisolini E; Bucci E; Perera T; Isella C; Medico E
Oncotarget; 2015 Jan; 6(1):221-33. PubMed ID: 25473895
[TBL] [Abstract][Full Text] [Related]
16. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
[TBL] [Abstract][Full Text] [Related]
17. Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.
Funakoshi Y; Mukohara T; Tomioka H; Ekyalongo RC; Kataoka Y; Inui Y; Kawamori Y; Toyoda M; Kiyota N; Fujiwara Y; Minami H
Invest New Drugs; 2013 Oct; 31(5):1158-68. PubMed ID: 23568717
[TBL] [Abstract][Full Text] [Related]
18. A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers.
Fujita R; Blot V; Wong E; Stewart C; Lieuw V; Richardson R; Banah A; Villicana J; Timmer A; Coronella J; Newman R; Gymnopoulos M
Cancer Biol Ther; 2020 Jun; 21(6):549-559. PubMed ID: 32192391
[TBL] [Abstract][Full Text] [Related]
19. A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers.
Meng L; Shu M; Chen Y; Yang D; He Q; Zhao H; Feng Z; Liang C; Yu K
Cancer Biol Ther; 2014 Jun; 15(6):721-34. PubMed ID: 24618813
[TBL] [Abstract][Full Text] [Related]
20. The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress.
Wang X; Wang S; Liu Y; Ding W; Zheng K; Xiang Y; Liu K; Wang D; Zeng Y; Xia M; Yang D; Wang Y
Biochem Biophys Res Commun; 2014 Mar; 446(1):160-6. PubMed ID: 24582562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
